A calixarene compound represented by formula (1) below is provided. The calixarene compound contains, per molecule, at least one —CH.sub.2OH group or phenolic hydroxy group and at least one carbon-carbon unsaturated bond. R.sup.1's are a structural moiety (A), which has a —CH.sub.2OH group; a structural moiety (B), which has a carbon-carbon unsaturated bond; a structural moiety (C), which has a —CH.sub.2OH group and a carbon-carbon unsaturated bond; a monovalent organic group (D), which is different from (A), (B), and (C); or a hydrogen atom (E). R.sup.2's are (A), (B), (C), (D), or (E) provided that not all R.sup.2's are (E). R.sup.3's are one of a hydrogen atom, an aliphatic hydrocarbon group, and an aryl group, n is 2 to 10. * is a point of attachment to an aromatic ring. A curable composition including the calixarene compound is provided. A cured product of the curable composition is provided ##STR00001##

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

Described are polymerizable high energy light absorbing compounds of formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and X are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

A mild and efficient synthesis of primary amines and amides from aldehydes or ketones using a heterogeneous metal catalyst and amine donor is disclosed. The initial heterogeneous metal-catalyzed reaction between the carbonyl and the amine donor components is followed by the addition of a suitable acylating agent component in one-pot, thus providing a catalytic one-pot three-component synthesis of amides. Integration of enzyme catalysis allows for eco-friendly one-pot co-catalytic synthesis of amides from aldehyde and ketone substrates, respectively. The process can be applied to asymmetric synthesis or to the co-catalytic one-pot three-component synthesis of capsaicin and its analogues from vanillin or vanillyl alcohol. A co-catalytic reductive amination/dynamic kinetic resolution (dkr) relay sequence for the asymmetric synthesis of optically active amides from ketones is disclosed. Implementation of a catalytic reductive amination/kinetic resolution (kr) relay sequence produces the corresponding optically active amide product and optical active primary amine product with the opposite stereochemistry from the starting ketones.

A mild and efficient synthesis of primary amines and amides from aldehydes or ketones using a heterogeneous metal catalyst and amine donor is disclosed. The initial heterogeneous metal-catalyzed reaction between the carbonyl and the amine donor components is followed by the addition of a suitable acylating agent component in one-pot, thus providing a catalytic one-pot three-component synthesis of amides. Integration of enzyme catalysis allows for eco-friendly one-pot co-catalytic synthesis of amides from aldehyde and ketone substrates, respectively. The process can be applied to asymmetric synthesis or to the co-catalytic one-pot three-component synthesis of capsaicin and its analogues from vanillin or vanillyl alcohol. A co-catalytic reductive amination/dynamic kinetic resolution (dkr) relay sequence for the asymmetric synthesis of optically active amides from ketones is disclosed. Implementation of a catalytic reductive amination/kinetic resolution (kr) relay sequence produces the corresponding optically active amide product and optical active primary amine product with the opposite stereochemistry from the starting ketones.

A sugar surfactant of formula (I), where R.sup.1 is H or an alkyl group comprising 1 to 3 carbon atoms and R.sup.2 is a polyhydroxyhydrocarbyl group comprising a straight hydrocarbyl chain to which at least three hydroxyl groups are directly bonded, preferably a 2,3,4,5,6-pentahydroxyhex-1-yl group, is suitable especially for use in agrochemical adjuvant and active substance compositions.

##STR00001##

A genus of proteolysis-targeting chimeras (PROTACs)-type compounds/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized. ##STR00001##

A genus of proteolysis-targeting chimeras (PROTACs)-type compounds/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized. ##STR00001##